This is not the most recent version of this material.
For an updated version, please see the relevant topic page.
Asthma: Initial Draft Report
This draft report examines the comparative effectiveness and value of mepolizumab (Nucala, GlaxoSmithKline plc.) for the treatment of severe eosinophilic asthma. It includes a systematic review of the published evidence, as well as an economic analysis that examines cost-effectiveness and budget impact of the two interventions. The results of these analyses are used to produce an ICER value-based price benchmark the drug; these are prices that reflect the magnitude of estimated improvements in long-term patient outcomes and thresholds for new drug and device costs that do not exceed growth in the overall national economy.
This version of the report was open to a two week public comment period.View All Materials on this Topic or Go Back to View More Materials